In your initial post, respond to the following scenario (Hint: use the pharmgkb website to guide your responses):

  1. Before initiating abacavir, an anti-retroviral, for a newly diagnosed HIV positive patient the nurse practitioner orders HLA-B*5701 allele genetic testing. The test confirms that the patient carries the HLA-B*5701 allele.
    1. Describe what these results mean.
    2. Should the nurse practitioner prescribe abacavir in this case? If not, state why.
  2. A patient is prescribed antiplatelet therapy (clopidogrel) following an acute myocardial infarction (MI). Six months later, the patient suffers another acute MI. The patient has been adherent to therapy and the nurse practitioner suspects that clopidrogel may have been ineffective. How might genetic testing have been beneficial in this case?
  3. Identify 2 limitations of pharmacogenomics testing. Explain.
  4. Identify 2 ethical concerns of using pharmacogenomics testing. Explain.



Describe what these results mean

The rationale for HLA-B*5701 allele genetic testing is to establish the potential risk for developing side effects to a drug known as abacavir. Therefore, if the test confirms that the patient carries the HLA-B*5701 allele, it means that he or she has an HLA-B*5701 gene hence a high risk of developing a life-threatening reaction from the use of abacavir (Sousa-Pinto et al., 2015)….Please click the icon below to purchase full solution at $5